Strategies for recombinant production of antimicrobial peptides with pharmacological potential
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Introduction The need to develop new drugs for the control of pathogenic microorganisms has redoubled efforts to prospect for antimicrobial peptides (AMPs) from natural sources and to characterize its structure and function. These molecules present a broad spectrum of action against different microorganisms and frequently present promiscuous action, with anticancer and immunomodulatory activities. Furthermore, AMPs can be used as biopharmaceuticals in the treatment of hospital-acquired infections and other serious diseases with relevant social and economic impacts.Areas covered: The low yield and the therefore difficult extraction and purification process in AMPs are problems that limit their industrial application and scientific research. Thus, optimized heterologous expression systems were developed to significantly boost AMP yields, allow high efficiency in purification and structural optimization for the increase of therapeutic activity.Expert opinion: This review provides an update on recent developments in the recombinant production of ribosomal and non-ribosomal synthesis of AMPs and on strategies to increase the expression of genes encoding AMPs at the transcriptional and translational levels and regulation of the post-translational modifications. Moreover, there are detailed reports of AMPs that have already reached marketable status or are in the pipeline under advanced stages of preclinical testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032 · cited 2×
“be used to produce recombinant protein for biomedical and pharmaceutical research [196,198,200,201,203,204].”
BackgroundTherapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879 · cited 1×
“proteases, lose their activity influenced by low gastric pH, and/ or have little absorption in the intestinal epithelium [345,346].”
BackgroundBaculovirus as versatile vectors for protein expression in insect and mammalian cells
Kost, T. A., Condreay, J. P., & Jarvis, D. L. (2005) · Nature Biotechnology · doi:10.1038/nbt1095 · Cited by 1,014
Antibiotic resistance in Staphylococcus aureus. Current status and future prospects
Foster, T. J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux007 · Cited by 845
Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli
Sørensen, H. P., & Mortensen, K. K. (2005) · Microbial Cell Factories · doi:10.1186/1475-2859-4-1 · Cited by 841
Kim, J. Y., Kim, Y.-G., & Lee, G. M. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3758-5 · Cited by 801 · cited 2×
“be used to produce recombinant protein for biomedical and pharmaceutical research [196,198,200,201,203,204].”
BackgroundCultivation strategies to enhance productivity of Pichia pastoris: A review
Looser, V., Bruhlmann, B., Bumbak, F., Stenger, C., Costa, M., Camattari, A., Fotiadis, D., & Kovar, K. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.05.008 · Cited by 350 · cited 1×
“cerevisiae, Pichia pastoris (reclassified as Komagatella phaffii [136]) does not divert part of its carbon to ethanol production, allowing for high biomass as well as recombinant molecule production [108,110,137].”
BackgroundTherapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
Ritacco, F. V., Wu, Y., & Khetan, A. (2018) · Biotechnology Progress · doi:10.1002/btpr.2706 · Cited by 273
Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria
Robinson, M.-P., Ke, N., Lobstein, J., Peterson, C., Szkodny, A., Mansell, T. J., Tuckey, C., Riggs, P. D., Colussi, P. A., Noren, C. J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9072 · Cited by 131
Use of the SHuffle strains in production of proteins
Ren, G., Ke, N., & Berkmen, M. (2016) · Current Protocols in Protein Science · doi:10.1002/cpps.11 · Cited by 60
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Ngan, H. D., Huy, B. L., Uyen, C. L., Phuong, H. B. T., & Xuan, H. L. (2025) · European Food Research and Technology · doi:10.1007/s00217-025-04754-6 · Cited by 3
“In addition to the two methods mentioned above, large-scale AMPs can also be manufactured via recombinant production [89, 90 ].”
Metadata
- Authors
- Sampaio de Oliveira, K. B., Leite, M. L., Rodrigues, G. R., Duque, H. M., da Costa, R. A., Cunha, V. A., de Loiola Costa, L. S., da Cunha, N. B., Franco, O. L., & Dias, S. C.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2020-04-02
- Volume
- 13
- Issue
- 4
- Pages
- 367-390
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W3022848239
- Cited by
- 55
- References
- 11
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.